Viking Therapeutics (VKTX) Research & Development (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Research & Development for 12 consecutive years, with $153.5 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 395.24% to $153.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $345.0 million through Dec 2025, up 239.38% year-over-year, with the annual reading at $345.0 million for FY2025, 239.38% up from the prior year.
- Research & Development hit $153.5 million in Q4 2025 for Viking Therapeutics, up from $90.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $153.5 million in Q4 2025 to a low of $9.8 million in Q4 2021.
- Historically, Research & Development has averaged $30.5 million across 5 years, with a median of $17.3 million in 2022.
- Biggest five-year swings in Research & Development: decreased 12.32% in 2023 and later soared 395.24% in 2025.
- Year by year, Research & Development stood at $9.8 million in 2021, then skyrocketed by 64.29% to $16.2 million in 2022, then rose by 26.73% to $20.5 million in 2023, then surged by 51.14% to $31.0 million in 2024, then skyrocketed by 395.24% to $153.5 million in 2025.
- Business Quant data shows Research & Development for VKTX at $153.5 million in Q4 2025, $90.0 million in Q3 2025, and $60.2 million in Q2 2025.